CLAIMS

1. Use of a peptide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a bacterial infection in a subject, wherein the peptide comprises between 10 to 200 lysine or arginine amino acid residues.

2. The use of claim 1, wherein the peptide consists of between 10 to 50 arginine amino acid residues.

3. The use of claim 1, wherein the peptide comprises 100 to 200 contiguous lysine residues, and wherein the bacterial infection is caused by a pathogen selected from the group consisting of *Staphylococcus spp.*; *Pseudomonas spp.*; and *Propionibacterium spp.*.

4. The use of claim 3, wherein the subject is a mammal.

5. The use of claim 4, wherein the mammal is a human.

6. The use of claim 3, wherein the subject is a bird.

7. The use of claim 3, wherein the bacterial infection is a dermal infection.

8. The use of claim 3, wherein the pathogen is selected from the group consisting of: *Staphylococcus aureus*; and *Staphylococcus epidermidis*.

9. The use of claim 3, wherein the medicament is to be administered to the subject by a route selected from the group consisting of: oral, parenteral, rectal, dermal, transdermal, intrathoracic, intrapulmonary, and intranasal routes.

10. The use of claim 3, wherein the medicament is formulated for topical administration.

11. The use of claim 1, wherein the peptide consists of 100 to 200 contiguous lysine residues, and wherein the bacterial infection is caused by a pathogen selected from the group consisting of *Staphylococcus spp.*; *Pseudomonas spp.*; and *Propionibacterium spp.*.

12. The use of claim 11, wherein the subject is a mammal.

13. The use of claim 12, wherein the mammal is a human.

14. The use of claim 11, wherein the subject is a bird.

15. The use of claim 11, wherein the bacterial infection is a dermal infection.

16. The use of claim 11, wherein the pathogen is selected from the group consisting of: *Staphylococcus aureus*; and *Staphylococcus epidermidis.*

17. The use of claim 11, wherein the medicament is to be administered to the subject by a route selected from the group consisting of: oral, parenteral, rectal, dermal, transdermal, intrathoracic, intrapulmonary, and intranasal routes.

18. The use of claim 11, wherein the medicament is formulated for topical administration.